Author:
Alibhai Shabbir MH,Santa Mina Daniel,Ritvo Paul,Sabiston Catherine,Krahn Murray,Tomlinson George,Matthew Andrew,Segal Roanne,Warde Padraig,Durbano Sara,O’Neill Meagan,Culos-Reed Nicole
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference62 articles.
1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Society: Canadian Cancer Statistics 2014. Toronto, 2014
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
3. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–24.
4. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981–9.
5. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.